Study Title | Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) |
---|---|
Protocol ID | CDRB436G2201 |
Disease (Sub Disease) | Low grade glioma High grade glioma |
Diagnosis Stage | Relapse/refractory |
Sponsor | Novartis Pharmaceuticals |
Links | https://clinicaltrials.gov/ct2/show/NCT02684058 |
Trial Status | Closed to Recruitment |
Trial Open Date | 24/10/2017 |
Study Type | Treatment |
Phase | Phase 2 |
Age Eligibility | 12 Months to 17 Years |
International registry ID's | NCT02684058 |